

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported):  
**November 10, 2008**

**BIOSANTE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-31812**  
(Commission File Number)

**58-2301143**  
(I.R.S. Employer Identification Number)

**111 Barclay Boulevard**  
**Lincolnshire, Illinois**  
(Address of Principal Executive Offices)

**60069**  
(Zip Code)

**(847) 478-0500**  
(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Section 2 – Financial Information

### Item 2.02. Results of Operations and Financial Condition.

On November 10, 2008, BioSante Pharmaceuticals, Inc. publicly announced its financial results for the third quarter ended September 30, 2008. For further information, please refer to the press release attached hereto as Exhibit 99.1, which is incorporated by reference herein.

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

## Section 9 – Financial Statements and Exhibits

### Item 9.01. Financial Statements and Exhibits.

(c) *Exhibits.*

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued November 10, 2008

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: /s/ Phillip B. Donenberg  
Phillip B. Donenberg  
*Chief Financial Officer, Treasurer and Secretary*

Dated: November 10, 2008

---

BIOSANTE PHARMACEUTICALS, INC.

FORM 8-K  
Exhibit Index

**Exhibit No.**

**Description**

**Method of Filing**

99.1

Press Release issued November 10, 2008

Furnished herewith

FOR IMMEDIATE RELEASE

NASDAQ: BPAX

## **BioSante Pharmaceuticals Reports Third Quarter 2008 Financial Results LibiGel® Continues To Be Focus in Treatment of Female Sexual Dysfunction**

**LINCOLNSHIRE, Illinois - (November 10, 2008)** --- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported its financial results for the third quarter and nine months ended September 30, 2008, and stated that LibiGel (testosterone gel) for the treatment of female sexual dysfunction continues as BioSante's number one focus. LibiGel currently is in three Phase III clinical trials to support submission and approval of a new drug application (NDA) with the FDA. The LibiGel Phase III safety and efficacy trials are being conducted under an FDA approved SPA.

BioSante incurred a net loss of approximately \$6.6 million or (\$0.24) per share for the quarter ended September 30, 2008 and \$16.3 million or (\$0.60) per share for the nine months ended September 30, 2008, compared to a net loss of \$1.7 million or (\$0.06) per share and \$5.9 million or (\$0.24) per share for the same respective periods in 2007. The increased net loss was due primarily to anticipated increased expenses to conduct the three ongoing LibiGel Phase III clinical trials.

The Company's cash, cash equivalents and short-term investments as of September 30, 2008 were approximately \$17.5 million, as compared to approximately \$22.8 million as of June 30, 2008.

### **About BioSante Pharmaceuticals, Inc.**

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately \$2.5 billion and for oral contraceptives approximately \$3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: [www.biosantepharma.com](http://www.biosantepharma.com).

For more information, please contact:

McKinney/Chicago

Alan Zachary

(312) 944-6784 ext. 316;

[azachary@mckinneychicago.com](mailto:azachary@mckinneychicago.com);

Investor Relations:

The Investor Relations Group

Investors: Adam S. Holdsworth / Christine Berni 212-825-3210

or

Media: Laura Colontrelle /Janet Vasquez 212-825-3210

---

